ROSWELL PARK CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Narrative or Fact-Based Videos in Increasing Colorectal Cancer Screenings in African American Communities

Not Applicable

Completed

Conditions: Colorectal Cancer
Healthy, no Evidence of Disease

Interventions: Behavioral: behavioral intervention

First Posted Date: 2014-03-31

Last Posted Date: 2022-07-22

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 1310

Registration Number: NCT02100254

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
Mount Sinai School of Medicine, New York, New York, United States

Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Not Applicable

Completed

Conditions: Localized Non-Resectable Adult Hepatocellular Carcinoma
Stage IIIB Hepatocellular Carcinoma
Advanced Adult Hepatocellular Carcinoma
Stage IVB Hepatocellular Carcinoma
Stage III Childhood Hepatocellular Carcinoma
Stage IIIA Hepatocellular Carcinoma
Stage IIIC Hepatocellular Carcinoma
Stage IV Childhood Hepatocellular Carcinoma
Stage IVA Hepatocellular Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Sorafenib Tosylate

First Posted Date: 2014-02-26

Last Posted Date: 2022-07-25

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 30

Registration Number: NCT02072486

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer

Phase 2

Terminated

Conditions: Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary
Recurrent Laryngeal Squamous Cell Carcinoma
Recurrent Oropharyngeal Squamous Cell Carcinoma
Recurrent Oral Cavity Verrucous Carcinoma
Recurrent Laryngeal Verrucous Carcinoma
Tongue Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Photodynamic Therapy
Drug: Porfimer Sodium

First Posted Date: 2014-02-21

Last Posted Date: 2017-10-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 3

Registration Number: NCT02068157

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Dovitinib Lactate, Gemcitabine Hydrochloride, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Solid Tumors or Pancreatic Cancer

Phase 1

Withdrawn

Conditions: Recurrent Pancreatic Cancer
Stage IV Pancreatic Cancer
Duct Cell Adenocarcinoma of the Pancreas
Stage III Pancreatic Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: dovitinib lactate
Drug: gemcitabine hydrochloride
Drug: paclitaxel albumin-stabilized nanoparticle formulation
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2014-01-29

Last Posted Date: 2015-01-09

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT02048943

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Icotinib Hydrochloride in Treating Patients With Advanced Cancers

Phase 1

Withdrawn

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: icotinib hydrochloride
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2014-01-10

Last Posted Date: 2014-11-05

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT02033148

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2

Terminated

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Untreated Adult Acute Myeloid Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)

Interventions: Drug: cytarabine
Drug: omacetaxine mepesuccinate
Drug: decitabine
Other: laboratory biomarker analysis

First Posted Date: 2014-01-07

Last Posted Date: 2016-05-09

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 2

Registration Number: NCT02029417

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Are in Remission

Phase 1

Withdrawn

Conditions: Recurrent Fallopian Tube Cancer
Recurrent Ovarian Epithelial Cancer
Recurrent Primary Peritoneal Cavity Cancer
Stage IA Fallopian Tube Cancer
Stage IA Ovarian Epithelial Cancer
Stage IA Primary Peritoneal Cavity Cancer
Stage IB Fallopian Tube Cancer
Stage IB Ovarian Epithelial Cancer
Stage IB Primary Peritoneal Cavity Cancer
Stage IC Fallopian Tube Cancer

Interventions: Drug: IDO1 inhibitor INCB024360
Biological: ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine
Other: laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2013-11-13

Last Posted Date: 2013-12-18

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01982487

Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors

Phase 1

Withdrawn

Conditions: Recurrent Non-Small Cell Lung Carcinoma
Stage IIIA Non-Small Cell Lung Cancer
Stage IIIB Non-Small Cell Lung Cancer
Stage IV Non-Small Cell Lung Cancer
Adult Solid Neoplasm

Interventions: Drug: Buparlisib
Drug: Cisplatin
Drug: Gemcitabine Hydrochloride
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Other: Questionnaire Administration

First Posted Date: 2013-10-29

Last Posted Date: 2023-04-27

Lead Sponsor: Roswell Park Cancer Institute

Registration Number: NCT01971489

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma

Phase 1

Active, not recruiting

Conditions: Stage I Diffuse Large B-Cell Lymphoma
Stage III Diffuse Large B-Cell Lymphoma
CD20 Positive
Stage IV Diffuse Large B-Cell Lymphoma
Stage II Diffuse Large B-Cell Lymphoma
Recurrent Diffuse Large B-Cell Lymphoma
Refractory Diffuse Large B-Cell Lymphoma

Interventions: Drug: Carboplatin
Drug: Carfilzomib
Drug: Etoposide
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study
Biological: Rituximab

First Posted Date: 2013-10-10

Last Posted Date: 2024-08-02

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 29

Registration Number: NCT01959698

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Nintedanib in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Up to Two Previous Chemotherapy Regimens

Phase 2

Completed

Conditions: Recurrent Non-small Cell Lung Cancer
Stage III Non-small Cell Lung Cancer
Stage IV Non-small Cell Lung Cancer
Squamous Cell Lung Cancer

Interventions: Drug: nintedanib

First Posted Date: 2013-09-23

Last Posted Date: 2017-06-08

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 6

Registration Number: NCT01948141

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
University Hospitals Case Medical Center, Cleveland, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy